Original Publication Date: 1 May, 2016
Publication / Source: International Journal of Hematologic Oncology
Authors: John C Allen, Fatima Talab & Joseph R Slupsky
B-lymphocytes are dependent on B-cell receptor (BCR) signaling for the constant maintenance of their physiological function, and in many B-cell malignancies this signaling pathway is prone to aberrant activation. This understanding has led to an ever-increasing interest in the signaling networks activated following ligation of the BCR in both normal and malignant cells, and has been critical in establishing an array of small molecule inhibitors targeting BCR-induced signaling.